1-13 of 13
Naomi B. Haas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1540–1548.
https://doi.org/10.1158/1078-0432.CCR-21-2972
Published: 14 April 2022
View article titled, Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Open the PDF for Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial in another window
Includes: Supplementary data
Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Jr, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 831–839.
https://doi.org/10.1158/1078-0432.CCR-21-3238
Published: 03 March 2022
View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Open the PDF for From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit in another window
Journal Articles

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer

Tanya B. Dorff, Vivek Narayan, Stephen J. Forman, Peter D. Zang, Joseph A. Fraietta, Carl H. June, Naomi B. Haas, Saul J. Priceman
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 576–584.
https://doi.org/10.1158/1078-0432.CCR-21-1483
Published: 15 February 2022
View article titled, Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
Open the PDF for Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer in another window
Journal Articles

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Wenxin Xu, Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Venkata Sabbisetti, Rupal S. Bhatt
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3397–3403.
https://doi.org/10.1158/1078-0432.CCR-21-0025
Published: 15 June 2021
View article titled, Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Open the PDF for Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805) in another window
Includes: Supplementary data
Journal Articles

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

Wenxin Xu, Maneka Puligandla, Judith Manola, Andrea J. Bullock, Daniel Tamasauskas, David F. McDermott, Michael B. Atkins, Naomi B. Haas, Keith Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Rupal S. Bhatt
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6098–6106.
https://doi.org/10.1158/1078-0432.CCR-19-0818
Published: 15 October 2019
View article titled, Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Open the PDF for Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

Naomi B. Haas, Leonard J. Appleman, Mark Stein, Maryann Redlinger, Melissa Wilks, Xiaowei Xu, Angelique Onorati, Anusha Kalavacharla, Taehyong Kim, Chao Jie Zhen, Sabah Kadri, Jeremy P. Segal, Phyllis A. Gimotty, Lisa E. Davis, Ravi K. Amaravadi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2080–2087.
https://doi.org/10.1158/1078-0432.CCR-18-2204
Published: 01 April 2019
View article titled, Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Open the PDF for Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma

Cora N. Sternberg, Frede Donskov, Naomi B. Haas, Christian Doehn, Paul Russo, Mohamed Elmeliegy, Guillaume Baneyx, Hiya Banerjee, Paola Aimone, Robert J. Motzer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (13): 3005–3013.
https://doi.org/10.1158/1078-0432.CCR-17-2652
Published: 01 July 2018
View article titled, Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Open the PDF for Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Lucia B. Jilaveanu, Maneka Puligandla, Sarah A. Weiss, Xin Victoria Wang, Christopher Zito, Keith T. Flaherty, Marta Boeke, Veronique Neumeister, Robert L. Camp, Adebowale Adeniran, Michael Pins, Judith Manola, Robert S. DiPaola, Naomi B. Haas, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 217–223.
https://doi.org/10.1158/1078-0432.CCR-17-1555
Published: 02 January 2018
View article titled, Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805
Open the PDF for Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805 in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors

Clinton Yam, Xiaowei Xu, Michael A. Davies, Phyllis A. Gimotty, Jennifer J.D. Morrissette, Michael T. Tetzlaff, Khalida M. Wani, Shujing Liu, Wanleng Deng, Meghan Buckley, Jianhua Zhao, Ravi K. Amaravadi, Naomi B. Haas, Ragini R. Kudchadkar, Anna C. Pavlick, Jeffrey A. Sosman, Hussein Tawbi, Luke Walker, Lynn M. Schuchter, Giorgos C. Karakousis, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 22–32.
https://doi.org/10.1158/1078-0432.CCR-17-1807
Published: 02 January 2018
View article titled, A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Open the PDF for A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins, Janice J. Dutcher, George Wilding, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4048–4054.
https://doi.org/10.1158/1078-0432.CCR-15-0215
Published: 14 September 2015
View article titled, Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Open the PDF for Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 in another window
Includes: Supplementary data
Journal Articles

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Craig L. Slingluff, Jr., Gina R. Petroni, Walter C. Olson, Mark E. Smolkin, Merrick I. Ross, Naomi B. Haas, William W. Grosh, Marc E. Boisvert, John M. Kirkwood, Kimberly A. Chianese-Bullock
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7036–7044.
https://doi.org/10.1158/1078-0432.CCR-09-1544
Published: 11 November 2009
View article titled, Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8<sup>+</sup> and CD4<sup>+</sup> T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Open the PDF for Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8<sup>+</sup> and CD4<sup>+</sup> T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Macrophage Migration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell Lines

Kangshen Yao, Seiichiro Shida, Muthu Selvakumaran, Robert Zimmerman, Ephraim Simon, Jonathan Schick, Naomi B. Haas, Marge Balke, Howard Ross, Steven W. Johnson, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (20): 7264–7272.
https://doi.org/10.1158/1078-0432.CCR-05-0135
Published: 20 October 2005
View article titled, Macrophage Migration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell Lines
Open the PDF for Macrophage Migration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell Lines in another window
Journal Articles

Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: A Phase II Study

Naomi B. Haas, Mitchell Smith, Nancy Lewis, Lynn Littman, Gwen Yeslow, Indira D. Joshi, Anthony Murgo, Joyce Bradley, Robert Gordon, Hao Wang, Andre Rogatko, Gary R. Hudes
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 109–114.
Published: 01 January 2003
View article titled, Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: <subtitle>A Phase II Study</subtitle>
Open the PDF for Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: <subtitle>A Phase II Study</subtitle> in another window